← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2010First marketed drug
Jan 1, 2010First NDA
Sep 1, 2015Last known activity
Apr 14, 2022
Acquired by GlaxoSmithKline on Jan 22, 2019
Timeline
2010s
- Jan 1, 2010
Tesaro— Founded
- Mar 27, 2017
niraparib— NDA Organization
- Mar 27, 2017
niraparib— NDA Secondary Org
- Jan 22, 2019
GlaxoSmithKline— Acquired By
Drugs by trial phase (46 distinct, 66 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (6 own, 0 via acquisition)
Phase 2 (25 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Carcinosarcoma
- Cholangiocarcinoma
- Colorectal Neoplasms
- Cystadenocarcinoma, Serous
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Glioblastoma
- Glioma
- Head and Neck Neoplasms
- Hypersensitivity
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Prolymphocytic
- Leukemia, Prolymphocytic, T-Cell
- Liver Diseases
- Lung Neoplasms
- Lymphoma
- Lymphoma, Mantle-Cell
- Melanoma
- Mesothelioma
- Mixed Tumor, Mullerian
- Nausea
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Rectal Neoplasms
- Sarcoma
- Triple Negative Breast Neoplasms
- Uterine Cervical Neoplasms
- Vomiting
Marketed drugs (2)
Recent trials (50)
- NCT06964165Lead sponsorPhase 2Apr 14, 2022
- NCT04774419CollaboratorPhase 2Apr 2, 2021
- NCT04762901CollaboratorPhase 1Apr 1, 2021
- NCT04313504CollaboratorPhase 2Jun 1, 2020
- NCT03983993CollaboratorPhase 2Jun 1, 2020
- NCT04409002CollaboratorPhase 2May 31, 2020
- NCT04221503CollaboratorPhase 2Jan 31, 2020
- NCT04139902CollaboratorPhase 2Dec 15, 2019
- NCT04165772CollaboratorPhase 2Nov 30, 2019
- NCT04068753CollaboratorPhase 2Sep 30, 2019
- NCT04080284CollaboratorPhase 2Sep 1, 2019
- NCT03955978CollaboratorPhase 1Aug 31, 2019
- NCT03833479CollaboratorPhase 2Jul 31, 2019
- NCT03981796Lead sponsorPhase 3Jul 15, 2019
- NCT03945084CollaboratorPhase 2Jun 30, 2019
Details
- Founded
- Waltham, MA, US Jan 1, 2010
- First NDA
- Sep 1, 2015
- Last known activity
- Apr 14, 2022
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy